Orelabrutinib Combined With Lenalidomide and Immunochemotherapy for Relapsed/Refractory Primary Central Nervous System Lymphoma: A Retrospective Analysis of Case Series
BackgroundRelapsed/refractory (r/r) primary central nervous system lymphoma (PCNSL) is an intractable situation without sound treatment. Bruton’s tyrosine kinase (BTK) represents an attractive drug target in PCNSL. Orelabrutinib is a new-generation BTK inhibitor with high cerebrospinal fluid (CSF) c...
Main Authors: | Chuanwei Yang, Yong Cui, Xiaohui Ren, Ming Li, Kefu Yu, Shaoping Shen, Haihui Jiang, Mingxiao Li, Xiaokang Zhang, Xuzhe Zhao, Qinghui Zhu, Song Lin |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2022-06-01
|
Series: | Frontiers in Oncology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2022.901797/full |
Similar Items
-
Classification of Progression Patterns in Glioblastoma: Analysis of Predictive Factors and Clinical Implications
by: Haihui Jiang, et al.
Published: (2020-11-01) -
Differential Predictors and Clinical Implications Associated With Long-Term Survivors in IDH Wildtype and Mutant Glioblastoma
by: Haihui Jiang, et al.
Published: (2021-05-01) -
A prognostic estimation model based on mRNA-sequence data for patients with oligodendroglioma
by: Qinghui Zhu, et al.
Published: (2022-12-01) -
Corrigendum: Distinguishing Pseudoprogression From True Early Progression in Isocitrate Dehydrogenase Wild-Type Glioblastoma by Interrogating Clinical, Radiological and Molecular Features
by: Mingxiao Li, et al.
Published: (2021-05-01) -
Distinguishing Pseudoprogression From True Early Progression in Isocitrate Dehydrogenase Wild-Type Glioblastoma by Interrogating Clinical, Radiological, and Molecular Features
by: Mingxiao Li, et al.
Published: (2021-04-01)